Skip to main content

Table 3 Comparisons of parameters of lipid metabolism and liver and renal function in patients switched from other fibrates between baseline and 3 months (N = 14)

From: Effect and safety of pemafibrate for patients with type 2 diabetes mellitus and hypertriglyceridemia: a retrospective analysis of clinical data

 

Baseline

3 months

p value

Triglycerides (mg/dL)

207.7

(95.8)

130.8

(49.6)

0.004

HDL-C (mg/dL)

50.4

(6.4)

53.2

(9.8)

0.135

Triglyceride/HDL-C ratio

4.30

(2.28)

2.62

(1.23)

0.003

AST (IU/L)

32.3

(16.0)

26.4

(8.5)

0.074

ALT (IU/L)

35.4

(23.4)

25.3

(11.8)

0.044

ALP (IU/L)*

65.1

(19.8)

59.5

(20.5)

0.184

γGTP (IU/L)

61.4

(37.8)

40.3

(15.9)

0.034

Serum creatinine (mg/dL)

0.91

(2.00)

0.78

(0.13)

0.001

eGFR (mL/min/1.73 m2)

65.5

(13.5)

75.4

(9.6)

< 0.001

  1. Data are mean (standard deviation) values. P values are for comparisons between baseline and 3 months after the start of pemafibrate
  2. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine transaminase; ALP, alkaline phosphate; γGTP, γ-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate
  3. * The value of ALP measured by the JSCC method was converted to the value of the IFCC method
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us